3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
28
NIH
5
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
3
Lymphoid
2
Sarcoma
1
Plasma cell
1
Myeloid
1
Conditions
Multiple Myeloma
1
Hematologic Neoplasms
1
Interventions
Dexamethasone
48
Bortezomib
22
Lenalidomide
20
Cyclophosphamide
20
daratumumab
18
Calcium Dobesilate
15
Melphalan
13
Thalidomide
12
carfilzomib
9
pomalidomide
7
Prednisone
7
dexamethasone acetate
6
dexamethasone 21-phosphate
6
auricularum
6
Peripheral Blood Stem Cell Transplantation
6
Doxorubicin
6
isatuximab
5
Filgrastim
5
Vincristine
4
Interferon-alpha
3
Etoposide
3
selinexor
2
sargramostim
2
ixazomib
2
elotuzumab
2
cobimetinib
2
belantamab mafodotin
2
Steroids
2
Stem Cell Transplantation
2
Radiotherapy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Sirolimus
×
Plasma cell
×
Clear all
NCT01460420
2017-07-06
EMN-alloRIC
European Myeloma Network B.V.
Phase 1/2
Completed
49 enrolled